Trials / Completed
CompletedNCT03792750
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986205 | Specified Dose on Specified Day |
| BIOLOGICAL | Nivolumab | Specified Dose on Specified Day |
Timeline
- Start date
- 2018-12-31
- Primary completion
- 2020-12-18
- Completion
- 2020-12-18
- First posted
- 2019-01-03
- Last updated
- 2022-02-28
- Results posted
- 2022-02-28
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03792750. Inclusion in this directory is not an endorsement.